Heparin therapy is currently used throughout industrialized countries to treat the acute phase of stroke. It is astonishing to consider the disparity between the lack of large-scale multicenter controlled trials for heparin therapy and the proliferation of aspirin trials throughout the world. Perhaps with the launching of the new low-molecular-compound heparins, there will be opportunity to set up trial in order to try establishing the indications for early anticoagulation.